Patents Assigned to Transgene
  • Publication number: 20190144840
    Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.
    Type: Application
    Filed: January 25, 2019
    Publication date: May 16, 2019
    Applicant: Transgene S.A.
    Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
  • Publication number: 20190134190
    Abstract: The present invention generally relates to an immunostimulatory combination comprising a first composition comprising a therapeutic vaccine and a second composition comprising one or more TLR9 ligand(s) such as CpG-containing oligonucleotide(s) as well as the use of such a first composition in combination with said second composition for treating a subject in need thereof. A specific embodiment is directed to the combination of a vectorized therapeutic vaccine encoding antigen(s) and a CpG-containing oligonucleotide such as Litenimod. Embodiments also include kits comprising such compositions as well as methods for treating, preventing or inhibiting diseases, in particular proliferative diseases or infectious diseases comprising administration of such first and second compositions.
    Type: Application
    Filed: May 3, 2017
    Publication date: May 9, 2019
    Applicants: Transgene SA, Oligovax
    Inventors: Karola Rittner, Roland Kratzer, Antoine Carpentier
  • Publication number: 20190070285
    Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.
    Type: Application
    Filed: September 17, 2018
    Publication date: March 7, 2019
    Applicant: Transgene S.A.
    Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
  • Patent number: 10190105
    Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: January 29, 2019
    Assignee: Transgene S.A.
    Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
  • Patent number: 10143754
    Abstract: A method for treating type 1 and type 2 diabetes by administering an oral pharmaceutical formulation which comprises of insulin or its analogs amalgamated with suitable encapsulating agents and pharmaceutical excipients. The encapsulated pharmaceutical oral formulation protects insulin or its analogs from harsh milieu of the gastrointestinal tract and facilitates efficient delivery of insulin at targeted sites with sustained hypoglycemic activity.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: December 4, 2018
    Assignee: TRANSGENE BIOTEK LIMITED
    Inventors: Koteswara Rao Kollipara, Gregory John Russell Jones
  • Patent number: 10111947
    Abstract: The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected in the group of polyvinylpyrrolidone and derivatives thereof, (iii) at least one sugar, (iv) at least two different amino acids, (v) at least two pharmaceutical acceptable salts, wherein at least one of said salts is a phosphate salt and, optionally (vi) a pharmaceutical acceptable buffer. Such a formulation is particularly suitable for freeze-drying. The present invention also relates to the corresponding dry product, as well as its preparation process. The present invention also relates to a reconstituted material comprising said dry product, which can be administered to a patient in need thereof. Such formulation and reconstituted material are useful as vaccines, preferably for the treatment and/or the prevention of cancers, infectious diseases and/or autoimmune disorders.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: October 30, 2018
    Assignee: Transgene S.A.
    Inventors: Claude Sene, Mélina Chasle
  • Patent number: 10076570
    Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.
    Type: Grant
    Filed: March 17, 2012
    Date of Patent: September 18, 2018
    Assignee: Transgene S.A.
    Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
  • Patent number: 9982055
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: May 29, 2018
    Assignee: TRANSGENE S.A.
    Inventors: Hélène Haegel, Christine Thioudellet, Michel Geist, Benoit Grellier, Jean-Baptiste Marchand
  • Patent number: 9884080
    Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: February 6, 2018
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Publication number: 20180028626
    Abstract: The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s).
    Type: Application
    Filed: February 12, 2016
    Publication date: February 1, 2018
    Applicant: Transgene SA
    Inventors: Philippe Slos, Julie Hortelano, Karola Rittner, Xavier Preville
  • Publication number: 20170326230
    Abstract: The present invention relates to liquid formulations of poxvirus, in particular vaccinia virus, stable during storage. Such stable liquid formulations comprise a) a poxvirus, preferably a vaccinia virus, b) a pharmaceutically acceptable buffer, c) a monovalent salt, d) a pharmaceutically acceptable disaccharide or sugar alcohol, and e) a pharmaceutically acceptable chelating agent, wherein the pH of the formulation is comprised between 6.5 and 8.5.
    Type: Application
    Filed: December 1, 2015
    Publication date: November 16, 2017
    Applicant: Transgene SA
    Inventor: Mélina CHASLE
  • Patent number: 9687515
    Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: June 27, 2017
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Patent number: 9676859
    Abstract: The invention is generally directed to promoting dendritic cells (DCs), and optionally M1-type (macrophage M1 polarization), immune response by administering a compound that modulates macrophage polarization. The invention is directed to the use of an antibody able to bind to CSF-1R for modulating macrophage polarization. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-1R in a patient by assessing the in vivo or in vitro polarization of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-1R on a subject being treated.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: June 13, 2017
    Assignee: Transgene SA
    Inventors: Hélène Haegel, Rémy Hallet
  • Publication number: 20170157188
    Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
    Type: Application
    Filed: July 16, 2015
    Publication date: June 8, 2017
    Applicant: Transgene S.A.
    Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
  • Publication number: 20170145392
    Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.
    Type: Application
    Filed: December 5, 2016
    Publication date: May 25, 2017
    Applicant: Transgene S.A.
    Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
  • Publication number: 20170143780
    Abstract: The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising said oncolytic virus and said one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and said one or more immune checkpoint modulator(s).
    Type: Application
    Filed: July 16, 2015
    Publication date: May 25, 2017
    Applicants: Institut Gustave-Roussy, Transgene SA
    Inventors: Laurence Zitvogel, Xavier Preville, Laetitia Fend
  • Publication number: 20170072047
    Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.
    Type: Application
    Filed: July 6, 2016
    Publication date: March 16, 2017
    Applicant: Transgene S.A.
    Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt
  • Patent number: 9512412
    Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: December 6, 2016
    Assignee: Transgene S.A.
    Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
  • Publication number: 20160331823
    Abstract: The present invention relates generally to novel immunogenic combinations comprising or encoding at least two heterooligomeric mycobacterial antigens and preferably a fusion polypeptide comprising said two heterooligomeric mycobacterial antigens, where the mycobacterial antigens are selected from the group of Esx, PE and PPE antigens of a Mycobacterium species, particularly a Mycobacterium of the tuberculosis complex such as Mycobacterium tuberculosis (Mtb). The present invention also relates to vectors, host cells and compositions comprising or encoding said immunogenic combination as well as to methods for expressing and producing it. The present invention also relates to methods of using said immunogenic combination, fusion polypeptide, vector, host cell, composition particularly for inducing or stimulating an immune response with the goal of providing a protective response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection.
    Type: Application
    Filed: January 9, 2015
    Publication date: November 17, 2016
    Applicant: TRANSGENE SA
    Inventors: Jean-Baptiste MARCHAND, Nathalie SILVESTTRE, Francois PENIN
  • Patent number: 9428584
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: August 30, 2016
    Assignee: Transgene S.A.
    Inventors: Hèléne Haegel, Christine Thioudellet, Michel Geist, Benoît Grellier, Jean-Baptiste Marchand